Abstract
Patient satisfaction with 6-monthly versus 3-monthly paliperidone palmitate long-acting injectable for schizophrenia treatment – results from a phase-3, randomised, noninferiority study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
